Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01782313 · ClinicalTrials.gov registry record · Phase 2

A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma, sponsored by Northwestern University.

Completed
Registry status
Phase 2
Development phase
58
Enrollment target
5
Study locations

NCT01782313 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma that has completed, run by Northwestern University. The registered enrollment target is 58 participants, below the 83-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (30% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01782313, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 2
Development phase
58 participants
Enrollment target
5
Study locations

Study Summary

This study is for patients who have been diagnosed with soft tissue sarcoma that has spread (metastasized) or that is not eligible for removal by surgery. The purpose of this study is to determine how soft tissue sarcomas respond to treatment with an investigational drug called tivozanib. In some lab and clinical studies, tivozanib has been shown to interfere with the growth of some types of tumors. The study will also evaluate how safe the study treatment is by observing how many and what kind of adverse events (side effects) participants experience.

Conditions Studied

Recurrent Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG tivozanib

Study Locations (5)

Illinois

  • Northwestern University - Chicago

Iowa

  • University of Iowa - Iowa City

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University - St Louis

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2013-03-06
Est. Completion 2016-12-28
Phase Phase 2

Sponsor

Northwestern University

1,209 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01782313

The ClinicalTrials.gov registry entry for NCT01782313 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (30% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.

NCT01782313 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Iowa, Minnesota.

Frequently Asked Questions

What is clinical trial NCT01782313 about?

NCT01782313 is a clinical study titled "A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas". This study is for patients who have been diagnosed with soft tissue sarcoma that has spread (metastasized) or that is not eligible for removal by surgery. The purpose of this study is to determine how soft tissue sarcomas respond to treatment with an investigational drug called tivozanib. In some la...

What is the current status of trial NCT01782313?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2013-03-06. Estimated completion is 2016-12-28.

What conditions does trial NCT01782313 study?

This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma.

What interventions are being tested in trial NCT01782313?

The interventions under investigation include: laboratory biomarker analysis (OTHER), tivozanib (DRUG).

Who is sponsoring clinical trial NCT01782313?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01782313 being conducted?

This trial has 5 study locations across Illinois, Iowa, Minnesota, Missouri, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Adult Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Adult Soft Tissue Sarcoma

All registered trials for this condition

Stage IV Adult Soft Tissue Sarcoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.